ArticleFrontiers in immunology2025

Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: a real-world analysis.

Chien-Hsiang Kao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.